SCHEMBL4833036

SCHEMBL4833036

C(=C/n1cncn1)\c1cnc2[nH]ccc2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 3/20 0.40
PIK3CD O00329 1/20 0.40
PIK3CB P42338 1/20 0.40
PIK3CG P48736 1/20 0.40
CDK8 P49336 6/20 0.38
AXL P30530 2/20 0.38
RIPK1 Q13546 4/20 0.38
KDR P35968 3/20 0.36
FGFR1 P11362 2/20 0.36
NUDT1 P36639 1/20 0.35
BRD4 O60885 1/20 0.33
PLK4 O00444 1/20 0.33
CHEK1 O14757 1/20 0.33
PDPK1 O15530 1/20 0.33
DYRK3 O43781 1/20 0.33
JAK2 O60674 1/20 0.33
ROCK2 O75116 1/20 0.33
PRKD3 O94806 1/20 0.33
MAP4K4 O95819 1/20 0.33
ABL1 P00519 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4833042 1.00 PIK3CA (0.40) PIK3CAPIK3CDPIK3CBPIK3CGCDK8
SCHEMBL14702331 0.71 CDK8 (0.58) PIK3CAPIK3CDPIK3CBPIK3CGCDK8
SCHEMBL299270 0.69 CDK8 (0.63) PIK3CAPIK3CDPIK3CBPIK3CGCDK8
SCHEMBL12459720 0.69 CDK8 (0.50) PIK3CAPIK3CDPIK3CBPIK3CGCDK8
SCHEMBL31152348 0.69 CDK8 (0.63) PIK3CAPIK3CDPIK3CBPIK3CGCDK8
SCHEMBL14026564 0.68 GRM5 (0.40)
SCHEMBL4823513 0.68 FGFR1 (0.50) PIK3CAPIK3CDPIK3CBPIK3CGCDK8
SCHEMBL16026878 0.68 RAB9A (0.56) PIK3CAPIK3CDPIK3CBPIK3CGCDK8
SCHEMBL16026877 0.68 RAB9A (0.56) PIK3CAPIK3CDPIK3CBPIK3CGCDK8
SCHEMBL8927087 0.67 CYP19A1 (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7446199-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-04 US disclosed
US-7446199-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-04 US disclosed
US-7446199-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-04 US disclosed
EP-1664043-B1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2007-11-14 EP disclosed
EP-1664043-B1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2007-11-14 EP disclosed
US-20050137201-A1 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED 2005-06-23 US disclosed
WO-2005028475-A2 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137201-A1 Compositions useful as inhibitors of protein kinases MAP3K20, PACSIN2, MAP3K6 PIK3CA 40/4885PIK3CD 64/4885PIK3CB 54/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.